Sintilimab Injection.

Sintilimab can be used for the treatment of classical Hodgkin’s lymphoma, non-small cell lung cancer and hepatocellular carcinoma.
It is contraindicated for patients who are allergic to this product or any of the excipients in this product.
It is recommended to conduct baseline tests including thyroid function and myocardial enzymes before treatment, and regularly monitor the treatment response and… Details 
Comprehensive interpretation of Sintilimab

Effects and efficacy:
This product can be used for the treatment of classical Hodgkin’s lymphoma, non-small cell lung cancer and hepatocellular carcinoma.
Dosage and administration:
This product must be used under the guidance of a physician with experience in tumor treatment. This product is administered by intravenous infusion. The recommended dose for intravenous infusion of this product is 200 mg, administered once every 3 weeks until disease progression or intolerable toxicity occurs. The intravenous infusion time should be within 30 to 60 minutes. When Sintilimab is administered in combination with chemotherapy, Sintilimab should be given first. When Sintilimab is administered in combination with bevacizumab, Sintilimab should be given first, with an interval of at least 5 minutes. It is recommended to give bevacizumab on the same day. Depending on the safety and tolerance of individual patients, it may be necessary to suspend or permanently discontinue the drug. Increasing or decreasing the dose is not recommended. If you find any inconsistency in the drug instructions before taking the drug, please consult your doctor or pharmacist in time.
Drug contraindications:
Allergic to this product is prohibited. Children should not use it with caution. Driving should be used with caution. People with liver and kidney dysfunction should use it with caution.
Related dosage forms:
Injection